Helsinn and Xediton Sign Exclusive License and Distribution Agreement for TRUSELTIQ™ (infigratinib) in Canada

Lugano, Switzerland, and Mississauga, Ontario, Dec. 20 (Korea Bizwire) – Helsinn Group (Helsinn), a Swiss Biopharmaceutical Group with an innovative R&D pipeline in cancer supportive care and oncology therapeutics, strategically investing in a fully integrated targeted therapy structure to develop, manufacture and commercialize small molecules in precision medicine with higher market potential, and Xediton Pharmaceuticals Inc. (Xediton), a Canadian [...]